Episurf Medical is preparing to launch patient-specific Episealer® implants to treat osteochondral lesions of the talus in the ankle. The company seeks to perform first procedures in 2Q18.
This represents a new direction for the technology which Episurf has developed to treat damaged knee cartilage, with a patient-specific design based on medical imaging and 3D modeling. (Three Episealer knee devices are approved and commercialized in Europe, presently.)
In 2016, a surgeon implanted one patient in Germany with a custom-made Episurf device to treat an ankle joint lesion. The device was built to the surgeon’s specifications in a complex case for which a patient-specific implant was reported to be the only option. The procedure was deemed successful and the patient reported excellent results at 12-month follow-up.
Present approaches to treat osteochondral talus defects include arthroscopic debridement and bone marrow stimulation, autograft transfer, autogenous cancellous bone graft, ACI, metal resurfacing, etc.
Source: Episurf Medical AB
Episurf Medical is preparing to launch patient-specific Episealer® implants to treat osteochondral lesions of the talus in the ankle. The company seeks to perform first procedures in 2Q18.
This represents a new direction for the technology which Episurf has developed to treat damaged knee cartilage, with a patient-specific design based on...
Episurf Medical is preparing to launch patient-specific Episealer® implants to treat osteochondral lesions of the talus in the ankle. The company seeks to perform first procedures in 2Q18.
This represents a new direction for the technology which Episurf has developed to treat damaged knee cartilage, with a patient-specific design based on medical imaging and 3D modeling. (Three Episealer knee devices are approved and commercialized in Europe, presently.)
In 2016, a surgeon implanted one patient in Germany with a custom-made Episurf device to treat an ankle joint lesion. The device was built to the surgeon’s specifications in a complex case for which a patient-specific implant was reported to be the only option. The procedure was deemed successful and the patient reported excellent results at 12-month follow-up.
Present approaches to treat osteochondral talus defects include arthroscopic debridement and bone marrow stimulation, autograft transfer, autogenous cancellous bone graft, ACI, metal resurfacing, etc.
Source: Episurf Medical AB
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.